An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...

The S&P 500 declined by 0.5% on Friday, Jan. 31, as investors digested the White House’s proposed tariffs on Canada, China, and Mexico.

On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...